Abstract: The present invention relates to FTCD antigen which is liver specific to serve as a diagnostic tool for Autoimmune Hepatitis type II. There is provided a human liver specific FTCD antigen recognized by LC1 antibodies which essentially consists in the amino acid sequence of SEQ ID NOS:3 and 4 or variants thereof which are recognized by LC1 antibodies. There is also disclosed a method of diagnosis of Autoimmune Hepatitis (AIH) type II disease in a patient biological sample, which comprises the steps of: a) subjecting a Western Blot having bound thereto an FTCD antigen of the present invention with the patient biological sample; and b) detecting the presence of LC1 antibodies in the sample; whereby the presence of LC1 antibodies is indicative of AIH type II disease.
Abstract: The present invention relates to a new class of G-protein-coupled receptor antagonists which bind to the intracellular molecular interface between the receptor and the G-protein, thus hampering signal transduction. The present invention describes peptide sequences derived from the prostaglandin receptor F2&agr; and the G-protein, G&agr;q protein. produced by molecular biology techniques or chemical synthesis, as selective inhibitors of signal transduction involved in the stimulation of this receptor. Such peptides or molecules derived from their primary, secondary and tertiary structures may be used as effective tocolytics for the prevention of premature labor or be utilized for the treatment of dysmenorrhea.
June 22, 2000
Date of Patent:
October 9, 2001
Hô ;pital Sainte-Justine
Sylvain Chemtob, Krishna G. Peri, Michel Potier